To describe a 3 years experience of peripheral arterial embolization with Micro Vascular Plug (MVP) (Medtronic, USA). The following parameters were investigated: type of vascular injury, anticoagulation therapy at time of procedure, anatomical district, caliper of the target artery, course of the landing zone, additional embolics, technical and clinical success, device related clinical complications. Technical success was defined as complete embolization without deployment of additional embolics after MVP release. Primary clinical success was considered as hemodynamic stability in emergency setting and resolution of the underlying vascular pathology in elective cases; secondary clinical success was considered clinical success after a second embolization session. 116 MVP have been released in 104 patients (67 males and 37 females; mean age 61.3 years). The pullback release technique was adopted in each case. 85 patients were treated in emergent settings while in 19 patients the procedure was scheduled. The overall technical success was 75%. Primary clinical success was 96.1%, secondary clinical success 3% and clinical failure 0.9%. No statistical differences in terms of effectiveness were observed among patients assuming anticoagulation (p-value = 0.6). A straight and longer landing zone were statistically associated with higher technical success compared to curved and shorter ones, (p-values < 0.001 and = 0.048 respectively). MVP-3 and MVP-5 were the most frequently adopted models in this sample, in 29.8% and 49% of the patients respectively. No clinically adverse events directly related to MVP occurred; in 3 cases device migration was registered without clinical complications. MVP is a safe and effective embolic agent. While eventual concomitant anticoagulation therapy did not influence the technical outcome, straight course and length of the landing zone are essential parameters to evaluate before deployment.

中文翻译：

---

MVP (Micro Vascular Plug ^® )栓塞：104 名患者在紧急和选择性情况下的经验

描述 3 年微血管栓塞 (MVP)（美敦力，美国）外周动脉栓塞的经验。研究了以下参数：血管损伤类型、手术时的抗凝治疗、解剖区、目标动脉的卡尺、着陆区的过程、额外的栓塞、技术和临床成功、设备相关的临床并发症。技术成功被定义为在 MVP 发布后没有部署额外栓塞的完全栓塞。主要临床成功被认为是紧急情况下的血流动力学稳定性和选择性病例中潜在血管病理学的解决；第二次栓塞治疗后第二次临床成功被认为是临床成功。104 名患者（67 名男性和 37 名女性；平均年龄 61 岁）中释放了 116 MVP。3年）。在每种情况下都采用了回拉释放技术。85 名患者在紧急情况下接受了治疗，而在 19 名患者中安排了手术。总体技术成功率为 75%。主要临床成功率为 96.1%，次要临床成功率为 3%，临床失败率为 0.9%。在接受抗凝治疗的患者中，未观察到有效性方面的统计学差异（p 值 = 0.6）。与弯曲和较短的着陆区相比，直的和较长的着陆区在统计上与更高的技术成功相关（p 值分别 < 0.001 和 = 0.048）。MVP-3 和 MVP-5 是该样本中最常采用的模型，分别为 29.8% 和 49% 的患者。未发生与 MVP 直接相关的临床不良事件；在 3 个案例中，设备迁移没有出现临床并发症。MVP 是一种安全有效的栓塞剂。虽然最终伴随的抗凝治疗不会影响技术结果，但着陆区的直线路线和长度是部署前评估的重要参数。